Novosom Overview

  • Founded
  • 1999

  • Status
  • Acquired/​Merged

  • Employees
  • 11

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5M

Novosom General Information


Developer of biopharmaceutical-based charge-reversible liposomal technology designed for the delivery of DNA based therapeutics. The company offers Smartycles, a technology that allows the delivery of active substances, such as siRNA, antisense and decoy oligonucleotides inside the cell either for topical or systemic applications and CD40 antagonist, an antisense oligonucleotide for inflammatory diseases and B-cell cancers. It also provides therapeutic products addressing inflammation, oncology and liver diseases.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Therapeutic Devices
Primary Office
  • Weinbergweg 22
  • 06120 Halle
  • Germany

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novosom Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 28-Jul-2010 $5M 000 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Novosom’s complete valuation and funding history, request access »

Novosom Patents

Novosom Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-102007029471-A1 New optional cationic sterols Withdrawn 20-Jun-2007 0000000000 0
EP-1938843-A1 Lipids and lipid assemblies comrising transfection enhancer elements Withdrawn 19-Dec-2006 00000000000 0
EP-1911443-A1 Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome Withdrawn 13-Oct-2006 000000000 0
DE-102006054192-A1 Method for loading nucleic acid active substances within amphoteric liposomes, comprises: mixing lipid mixture solution and aqueous solution of nucleic acid active substances; and sterile filtrating the liposomes containing the substances Ceased 17-Mar-2006 00000000000 0
EP-1764089-A1 Serum stable liposomes comprising amphoter ii lipid mixtures Withdrawn 15-Sep-2005 A61K9/1272
To view Novosom’s complete patent history, request access »

Novosom Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novosom Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
IBG Beteiligungsgesellschaft Sachsen-Anhalt Venture Capital Minority 000 0000 000000 0
bmp Ventures Venture Capital Minority 000 0000 000000 0
To view Novosom’s complete investors history, request access »